ArticleWorld journal of clinical cases2022
Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis.
Article in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biological Therapy and Small Molecules for Adults With Crohn's Disease: Systematic Review and Network Meta-Analysis.Pharmacotherapy · 2025Pooled it
- Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.Inflammopharmacology · 2024Trial
- Leucine-rich alpha-2 glycoprotein as a predictor of primary non-response to anti-TNF-α therapy in biologic-naïve Egyptian IBD patients.BMC gastroenterology · 2026Article
- Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease.Digestive diseases and sciences · 2026Article
- Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025).Journal of managed care & specialty pharmacy · 2026Article
- Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Patients With Inflammatory Bowel Disease: A Real-World Comparison of Combination Therapy Versus Monotherapy.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Distinct B Cell Subsets Changes as Potential Biomarkers of Response to Biologic Therapy in Crohn's Disease.International journal of molecular sciences · 2025Article
- A case of pulmonary and cutaneous sarcoidosis.Breathe (Sheffield, England) · 2025Article
- Review
- Narrative review of adalimumab for the treatment of cardiac sarcoidosis.Heart rhythm O2 · 2025Review
- Review
- Biologics for Inflammatory Bowel Disease in Clinical Practice: A Calabria (Southern Italy) Prospective Pharmacovigilance Study.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdalimumab (ADA) and infliximab (IFX) are the cornerstones of the treatment of Crohn's disease (CD). It remains controversial whether there is a difference in the effectiveness and safety between IFX and ADA for CD.
aimTo perform a meta-analysis to compare the effectiveness and safety of ADA and IFX in CD.
methodsPubMed, Embase, Cochrane Library, and Web of Science databases were searched. Cohort studies were considered for inclusion. The primary outcomes were induction of response and remission, maintenance of response and remission, and secondary loss of response. Adverse events were secondary outcomes.
resultsFourteen cohort studies were included. There was no apparent difference between the two agents in the induction response [odds ratio (OR): 1.27, 95% confidence interval (CI): 0.93-1.74,
conclusionADA and IFX have similar clinical benefits for anti-tumor necrosis factor-α naïve or non-naïve CD patients. Overall adverse events rate is higher in patients in the IFX group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.